Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2005-02-22
2005-02-22
Brusca, John (Department: 1631)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C424S001110, C424S130100, C530S387100, C530S388100, C530S388800
Reexamination Certificate
active
06858710
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, particularly ovarian cancer, are disclosed. Illustrative compositions comprise one or more ovarian tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly ovarian cancer.
REFERENCES:
patent: WO 0036107 (2000-06-01), None
patent: WO 0116318 (2001-03-01), None
patent: WO 0157272 (2001-08-01), None
patent: WO 0202587 (2002-01-01), None
patent: WO 0202624 (2002-01-01), None
patent: WO 0210187 (2002-02-01), None
patent: WO 0216429 (2002-02-01), None
patent: WO 0216581 (2002-02-01), None
Jin et al., “Human T cell leukemia virus type 1 oncoprotein tax targets the human mitotic checkpoint protein MA1,”Cell 93:81-91, Apr. 3, 1998.
Köhler et al., “Immunotherapy of Ovarian Carcinoma with the Monoclonal Anti-Idiotype Antibody ACA125—Results of the Phase LB Study,”Gebrutshilfe und Fraenheilkunde, 58(4):180-186, Apr. 1998.
Ma et al., “Use of encapsulated single chain antibodies for induction of anti-idiotypic humoral and cellular immune responses,”Journal of Pharmaceutical Sciences, 87(11):1375-1378, Nov. 1998.
Parker et al., “Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains,”The Journal of Immunology 152(1):163-175, Jan. 1, 1994.
Perez-Vilar and Hill, “The structure and assembly of secreted mucins,”The Journal of Biological Chemistry 274(45):31751-31754, Nov. 5, 1999.
Peoples et al., “Ovarian cancer-associated lymphocyte recognition of folate binding protein peptides,”Annals of Surgical Oncology, 5(8):743-750, Dec. 1998.
Schena et al., “Parallel human genome analysis: Microarray-based expression monitoring of 1000 genes,”Proc. Natl. Acad. Sci., 93:10614-10619, Oct. 1996.
Yee et al., “Isolation of tyrosinase-specific CD8+and CD4+T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus,”The Journal of Immunology 157: 4079-4086, 1996.
Bookman et al., “Biological therapy of ovarian cancer: Current directions,”Seminars in Oncology, 25(3):381-396, 1998.
Gibson et al., “Novel method for real time quantitative RT-PCR,”Genome Research 6:995-1001, Oct. 1996.
Gillespie et al., “Mage, Bage and Gage: Tumour antigen expression in benign and malignant ovarian tissue,”British Journal of Cancer, 78(6):816-821, Sep. 1998.
Heid et al., “Real time quantitative PCR,”Genome Research 6:986-994; Oct. 1996.
Heller et al., “Discovery and analysis of inflammatory disease-related genes using cDNA microarrays,”Proc. Natl. Acad. Sci. USA 94:2150-2155, Mar. 1997.
Ishikawa et al., “Prediction of the coding sequence of unidentified human genes. The complete sequence of 100 new cDNA clones from brain which can code for large proteins in vitro,”DNA Res., 5:169-176, 1998.
Hovig, E. et al., “CA 125: The End of the Beginning,”Tumor Biology 22: 345-347, 2001.
O'Brien, T.J. et al., “The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular Superstructure,”Tumor Biology 23: 154-169, 2002.
O'Brien, T.J. et al., “The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat Sequences,”Tumor Biology 22: 348-366, 2001.
Schummer, M. et al., “Comparative hybridization of an array of 21 500 ovarian cDNAs for the discovery of genes overexpressed in ovarian carcinomas,”Gene 238: 375-385, 1999.
Whitehouse, C. et al., “NBR1 interacts with fasciculation and elongation protein zeta-1 (FEZ1) and calcium and integrin binding protein (CIB) and shows developmentally restricted expression in the neural tube,”Eur. J. Biochem. 269: 538-545, 2002.
Yin and Lloyd, “Molecular Cloning of the CA125 Ovarian Cancer Antigen. Identification as a new mucin, MUC16,”Journal of Biological Chemistry 276(29): 27371-27375, Jul. 20, 2001.
Yin, B.W.T. et al., “Ovarian cancer antigen CA125 is encoded by theMUC16mucin gene,”International Journal of Cancer 98: 737-740, 2002.
Bangur Chaitanya S.
Fanger Gary R.
Hill Paul
Retter Marc W.
Corixa Corporation
Seed IP Law Group PLLC
LandOfFree
Compositions and methods for the therapy and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the therapy and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the therapy and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3495236